Top Stories
The site, which will serve patients in the US and globally, is expected to create around 600 high-value jobs.
According to Hansoh, a Tagrisso data-protection issue prompted the withdrawal, but a resubmission for the lung cancer treatment is planned.
Somnivera, whose principal investors include ARCH Venture Partners, F-Prime Capital and Population Health Partners, was established in August to develop therapies for sleep disorders.
The partnership, potentially worth over $7.5B, includes Abogen's lead asset, an mRNA-encoded CD19xCD3 T-cell engager dubbed ABO2203.
Ptarmigan-1 could expand access to the roughly 40% of the human proteome that traditional structure-based methods have struggled to tackle.
Conference News
SHANGHAI and HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering,...
RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and i...
NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencelOne clinical abstr...
